Results 211 to 220 of about 9,364,051 (364)

Coeliac disease

Journal of Clinical Pathology, 2005
G. Corazza, Dr V Villanacci
semanticscholar   +1 more source

Immune cell infiltration correlates with intestinal permeability, inflammation, and gastrointestinal symptoms in type 1 diabetes

Journal of Diabetes Investigation, EarlyView.
In individuals with type 1 diabetes, immune cell infiltration in the colon mucosa tended to correlate with fecal and systemic markers of intestinal permeability and inflammation, as well as gastrointestinal symptoms. These findings suggest that low‐grade gut immune activation might link the intestinal barrier dysfunction with systemic endotoxin ...
Polina Zalizko, Reinis Isaks, Leonora Pahirko, Aleksejs Fedulovs, Eduards Krustins, Jurijs Nazarovs, Sergejs Dubencovs, Hanne Salmenkari, Markku Lehto, Kaspars Jēkabsons, Una Riekstiņa, Per‐Henrik Groop, Niina Sandholm, Jeļizaveta Sokolovska   +13 more
wiley   +1 more source

Cultural Adaptation and Reliability Testing of the Coeliac Disease Food Attitudes and Behaviours Scale in Brazil. [PDF]

Nutrients
Ribeiro CDS, Nakano EY, Zandonadi RP.
europepmc   +1 more source

Plasma food antibodies during withdrawal and reintroduction of dietary gluten in coeliac disease. [PDF]

, 1973
F. Carswell, A Ferguson
openalex   +1 more source

The exposomal imprint on rosacea: More than skin deep

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Rosacea reflects systemic and environmental interactions, not just a skin disorder. Key factors include environmental triggers, genetic and microbiome influences, diagnostic gaps in skin of colour and social determinants. Advances in multi‐omics and exposome integration highlight pathways towards precision medicine, prevention and equitable, patient ...
Katerina Grafanaki, Daniella Bakoli Sgourou, Alexandros Maniatis, Efstathia Pasmatzi   +3 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Coeliac Disease [PDF]

BMJ, 1948
openaire   +4 more sources

Rethinking Coeliac Disease Diagnosis: Reflections on the 2025 ESsCD Guidelines. [PDF]

United European Gastroenterol J
Tye-Din JA.
europepmc   +1 more source

Coeliac Disease: Gluten Free Diet and… What Else?

, 2016
Marina Taus, Elsa Veronica Mignini, Daniele Fumelli, Debora Busni, Giulia Nicolai, C Carletti, Albano Nicolai   +6 more
openalex   +2 more sources

An infant with both cystic fibrosis and coeliac disease. [PDF]

, 1969
D. W. Hide, David Burman
openalex   +1 more source